July 23, 2017 3:44 AM ET


Company Overview of Allos Therapeutics, Inc.

Company Overview

Allos Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of anti-cancer therapeutics. It focuses on the development and commercialization of FOLOTYN (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is approved in the United States for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). It is also developing FOLOTYN in other hematologic malignancies. The company has a strategic collaboration agreement with Mundipharma International Corporation Limited (Mundipharma) to co-develop FOLOTYN. Allos Therapeutics, Inc. has commercialization rights for FOLOTYN in the United States and Canada; a...

11080 CirclePoint Road

Suite 200

Westminster, CO 80020

United States

Founded in 1992

111 Employees





Key Executives for Allos Therapeutics, Inc.

President and Secretary
Chief Financial Officer and Treasurer
Senior Vice President, General Counsel and Secretary
Age: 47
Senior Vice President of Corporate Development
Age: 51
Vice President of Biometrics and Statistics
Age: 63
Compensation as of Fiscal Year 2017.

Allos Therapeutics, Inc. Key Developments

Allos Therapeutics Inc., and Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. Enters into a Settlement Agreement to Resolve Patent Litigation Relating to Foloty

On May 27, 2016, Allos Therapeutics Inc., and Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc., entered into a settlement agreement to resolve their patent litigation relating to Folotyn (pralatrexate injection). As a result of the settlement, Dr. Reddy's will be permitted to market a generic version of Folotyn in the United States on December 1, 2022 or earlier under certain circumstances. Details of the settlement are confidential, and the parties will submit the agreement to the Federal Trade Commission and the Department of Justice. The parties will request that the court enter an order, in which it will dismiss the Company's litigation against Dr. Reddy's. As previously reported, the Company has also settled the litigation against Teva Pharmaceuticals USA, Inc. The Company's litigation against other generic filers continues.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Allos Therapeutics, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.